Decisions on how many YourPDX testing agents should be selected (treatment arms), and which anti-cancer therapies/therapeutic combinations should be tested, rest with the treating oncologist and the patient. Certis Oncology can also help identify therapeutic options upon request. Members of the Certis Oncology Medical Advisory Board may collaborate with you on these therapeutic testing strategies. You can also leverage our in-house bioinformatics team to help identify off-label and investigational therapies based on tumor genetics, as therapies that work for an individual cancer patient may sometimes fall outside those approved for a primary tumor diagnosis.